After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.

The brain-computer interface technology personalizes therapy based on an individual’s brain activity.

The Food and Drug Administration on Monday granted its first approval for a pacemaker-like device for the brain to ease symptoms of Parkinson's disease, which affects nearly 1 million people in the United States.

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.